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Alkaline phosphatase (ALP) ﬂare phenomenon documented as scintigraphic ﬂare phenomenon due to
elevated serum ALP levels produced by osteoblasts reﬂects an osteoblastic reaction in response to the
effective therapy of non-small cell lung cancer (NSCLC). Here, we report a case of ALP ﬂare following
geﬁtinib treatment for NSCLC. We also retrospectively analyzed the prevalence of ALP ﬂare in lung cancer
patients treated via epidermal growth factor receptor-tyrosine kinase inhibitor in our hospital. Recog-
nition of this phenomenon is important for physicians treating NSCLC patients to avoid discontinuation
of a potentially beneﬁcial treatment because of misdiagnosis for refractory multiple bone metastasis or
adverse effect.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Flare phenomenon on bone scintigraphy was ﬁrst documented
in 1970s [1] and is deﬁned based on an increase in the number of
lesions or intensity observed in a bone scan and the subsequent
decreased uptake of radiotracers in these lesions on repeated ex-
aminations. Flare phenomenon reﬂects a favorable response to
treatment, which has beenwell documented in prostate cancer and
breast cancer patients undergoing chemotherapy or hormone
therapy [2e4]. This phenomenon is typically observed approxi-
mately 3 weeks to 3 months following therapy [2,5,6]. Alkaline
phosphatase (ALP) ﬂare phenomenon has also been documented as
a scintigraphic ﬂare phenomenon, as elevated serum ALP levels
produced by osteoblasts reﬂect an osteoblastic reaction [2,4,7].
Both of these ﬂare phenomena are thought to occur in response to
effective therapy of non-small cell lung cancer (NSCLC).
Although reports have been ﬁled in recent years on ﬂare phe-
nomenon following anti-cancer chemotherapy in lung cancer
[5,8e12], little information is available regarding the incidence of
ALP ﬂare during anti-cancer chemotherapy, particularly among
patients treated with epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI).edicine, Saiseikai Kumamoto
4193, Japan. Tel.: þ81 96 351
Yasuda).
Ltd. This is an open access article uHere, we report a case of ALP ﬂare following geﬁtinib treatment
for NSCLC and the results of retrospective analysis of the prevalence
of ALP ﬂare in lung cancer patients treated with EGFR-TKI in our
hospital.Case
A 62-year-old man presenting with adenocarcinoma, multiple
lung nodules, hilar lymphadenopathy, and pleural disseminationwas
admitted to ourhospital (Fig.1). Geﬁtinibwas administered following
four cycles of cisplatin and pemetrexed. Serum alkaline phosphatase
(ALP) levels increased to 1.85 times admission levels following 2
weeks of geﬁtinib therapy. Although the patient's bone scan revealed
multiple hot spots, he denied pain (Fig. 2). We considered these
phenomena to be due to ﬂare phenomenon rather than treatment
failure, and geﬁtinib was therefore continued. Approximately one
month after geﬁtinib treatment, serum ALP levels returned to pre-
treatment values, and 2-[18F]ﬂuoro-2-deoxy-d-glucose/positron-
emission tomography (FDG/PET) indicatednouptakeof radiotracer in
the bone (Fig. 3). The patient received geﬁtinib for 119 days, and then
erlotinib was initiated 258 days later. However, the patient's disease
progressed, and he refused to remain on chemotherapy. The patient
died of cancer 635 days after diagnosis.
To analyze the prevalence of ALP ﬂare phenomenon, we retro-
spectively evaluated 224 NSCLC patients who received EGFR-TKI
treatment in the form of geﬁtinib (n ¼ 126) or erlotinib (n ¼ 98)
between April 2006 and September 2012 in our institution. Table 1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. 2-[18F]ﬂuoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)
performed before any treatment revealed increased uptake of radiotracer to the lesion
located in left lower lobe and multiple mediastinum and hilar lymph nodes not to any
bone area.
Fig. 3. FDG/PET performed 58 days after the start of geﬁtinib treatment revealed no
uptake of radiotracer to the tumor, bone, and lymph nodes. The clinician evaluated the
patient as partial response (PR) and continued geﬁtinib therapy.
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following EGFR-TKI treatment. We extracted those who experienced
transient elevation within 3 months of EGFR-TKI treatment and
examined their phenomena with regard to “ALP ﬂare”.
Eleven (5%) patients were extracted as having possible ALP ﬂare.
All patients had adenocarcinoma, but only 10 had a mutation in the
EGFR gene. In all cases, EGFR-TKI treatment was evaluated as partial
response (PR), and 8 patients had bone metastasis deﬁned by bone
scintigraphy or FDG/PET. In the geﬁtinib-treated group, 7 patients
(5.6%) exhibited ALP ﬂare, and the median time to ALP peak was 16
days (range8e28) after the initiationof geﬁtinib treatment. Baseline
ALP median was 783 (range 291e1324), and peak ALP median was
731 (range 568e3536). In the erlotinib-treated group, four patients
(4%) exhibited ALP ﬂare, and the median time to ALP peak was 18
days (range 7e101) following the initiation of erlotinib treatment.
Median baseline ALP was 586 (range 239e1012), and median peak
ALP 719 (range 401e1854). Serum ALP values returned to normal
range at a median of 114 days (range 35e197) (Table 1).
Discussion
We reported a case of ALP ﬂare following geﬁtinib treatment for
NSCLC and retrospectively evaluated the prevalence of ALP ﬂare in
lung cancer patients treated with EGFR-TKI in our hospital. TheFig. 2. Bone scintigraphy performed 14 days after the initiation of geﬁtinib treincidence of ﬂare was approximately 5% and occurred within
almost a month of EGFR-TKI therapy. These ﬁndings suggest that, in
certain cases, effective treatment of NSCLC may still be continued
even on recognition of ﬂare phenomenon.
Determining whether the adverse event was ALP ﬂare from new
bone metastasis (evaluated as disease progression [PD]) or due to
liver dysfunctionwas difﬁcult. Bone scan ﬂare is characterized by an
increase in uptake of radiotracer as a result of the stimulation of
osteoblastic activity during the repair process. A lytic lesion that
has been overlooked during a bone scan before therapy might also
present a new site of increased uptake and, therefore, be mis-
interpreted as indicating possible PD. Bone ALP is secreted by os-
teoblasts depending on the osteoblastic reaction, with serum ALP
often being elevated due to ALP ﬂare during bone scan ﬂare [7].
Itotani et al. (2012) reported 10 patients with liver dysfunction
during geﬁtinib treatment, which was detected at a median of 40
days after initiation of geﬁtinib [13]. Yoshimoto et al. also reported
5 cases of liver dysfunction detected between 28 and 56 days after
initiation of geﬁtinib treatment, 2 of which had ALP elevation in
association with transaminase elevation [14]. Given that this in-
terval resembles that of ﬂare phenomenon, it is difﬁcult to distin-
guish ALP ﬂare from liver dysfunction as an adverse effect. In our
case, both elevated serum ALP and uptake of radiotracer during
bone scan were observed. However, the patient denied experi-
encing bone pain, and the mass detected via chest X-ray wasatment revealed increased uptake of radiotracer in multiple bone lesions.
Table 1
Characteristics of patients who were observed ALP ﬂare during EGFR-TKI treatment.
No. Age Sex EGFR mutation Bone metastasis Baseline ALP Peak ALP (day) Baseline peak ratio Peakout ALP (day) Response Total medication (day)
1 54 F 19 deletions þ 783 1006 (8) 1.28 319 (115) PR 185
2 60 M 21 L858R þ 534 731 (9) 1.36 316 (32) PR 174
3 68 M 21 L858R unknown 385 554 (28) 1.43 293 (126) PR 196
4 74 F e þ 362 538 (16) 1.48 309 (44) PR 314
5 81 F 21 L858R þ 291 548 (12) 1.88 301 (40) PR 339
6 63 M 21 L858R unknown 530 1121 (18) 2.11 298 (66) PR 119
7 60 M 21 L858R þ 1324 3236 (15) 2.44 1065 (55) PR 56<
8 73 M 18 G719X þ 842 1009 (7) 1.2 350 (91) PR 182
9 73 F 19 deletions e 289 401 (101) 1.39 321 (136) PR 986<
10 80 M 19 deletions þ 239 429 (15) 1.79 238 (35) PR 255<
11 71 M 19 deletions þ 1012 1854 (21) 1.83 318 (197) PR 226
No.1e7: geﬁtinib group, No.8e11: erlotinib group.
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tion tests were also normal. We therefore continued geﬁtinib
treatment, and after approximately one month, serum ALP values
returned to pre-treatment levels, and FDG/PET did indicated no
radiotracer uptake in the bone. These ﬁndings suggest that physi-
cians should evaluate not only the bone scan but also clinical in-
formation, other serum liver function tests and other imaging
modalities, when we meet elevated serum ALP following EGFR-TKI
treatment. If an increase in ALP is observed during EGFR-TKI
treatment, particularly within 3 months and even in Grade 3 case
(Common Terminology Criteria for Adverse Events: CTCAE v4.0),
but is not accompanied by elevated transaminase, physicians might
not have to discontinue EGFR-TKI treatment.
We retrospectively evaluated the prevalence of ALP ﬂare in lung
cancer patients treated with EGFR-TKI in our hospital. The inci-
dence of ﬂare was approximately 5% and occurred within a month
of initiating EGFR-TKI therapy. Chao et al. (2009) observed that
bone scan ﬂare phenomenon was present in 21.2% of NSCLC pa-
tients treated with geﬁtinib and was detected an average of 40 days
after initiation of geﬁtinib treatment [5]. Colemann et al. (1988)
examined the correlation between responses to hormonal treat-
ment and alkaline phosphatase bone isozyme (ALP-BI) levels in 53
breast cancer patients [4]. According to their report, 1 month after
hormonal treatment, 16 patients achieved a partial response (PR),
and 15 (28%) experienced an increase in ALP-BI.
All patients who received EGFR-TKI treatment in our cases did
not have conﬁrmed bone metastasis before beginning of treat-
ment. The incidence of ALP ﬂare may increase if there are limited
cases of conﬁrmed bone metastasis before treatment. Conﬁrma-
tion of bone metastasis, however, might not be practical, as bone
scans are performed relatively infrequently. Although this was a
retrospective study, the result of an ALP peak being observed
within one month, but one case and ALP peak-out being observed
from 1 to 6 months ﬁt the criteria of bone scan ﬂare
phenomenon.
Conclusion
We reported one case of ALP ﬂare following geﬁtinib treatment
for NSCLC. Given the difﬁculty in distinguishing ALP ﬂare from new
bone metastasis or liver dysfunction as an adverse event,recognition of these phenomena is important for physicians treat-
ing NSCLC patients to avoid discontinuation of a potentially bene-
ﬁcial treatment. The incidence of ALP ﬂare was approximately 5% in
NSCLC treated by EGFR-TKI and occurred within 1 month of EGFR-
TKI therapy.References
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